NanoViricides, Inc. Announces Issuance of Fundamental Patents in
Australia and the Philippines

March 24, 2014 07:00 AM Eastern Daylight Time

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC)
(the "Company"), announced today that a fundamental PCT patent
application, on which the nanoviricides® technology is based, has
resulted in additional issued patents in Australia and the Philippines.

“The issuance of the Australian patent is of particular importance
because of the Company’s interest in pursuing the initial human clinical
trials in that country,” said Eugene Seymour, MD, MPH, CEO of the
Company, adding, “Australia offers significant advantages including
financial incentives that would help us speed the development of our
drugs towards licensure.”

The Australian and Philippine patents have been allowed with a very
broad range of claims to a large number of families of chemical
structure compositions, pharmaceutical compositions, methods of making
the same, and uses of the same.

“It is rewarding to see that both the Australian and Philippine patent
offices recognized the novelty and the broad utility of the entire
‘pi-polymer’ class of materials as defined by the inventors, and granted
a patent with sufficient scope to protect the whole of the invention,
for all foreseeable pharmaceutical applications,” said Dr. James Demers,
PhD, JD, Gotham Patent Services LLC, who represents the inventors and
directs the international patenting effort. He further added, “In
addition, the inventors have also filed an original PCT application that
covers the nanoviricides® anti-viral substances.”

These compositions result in self-assembling polymers that we call
“TheraCour®“ polymers (or “pi-polymers”), and possess significant
advantages over the earlier block-copolymer systems, hard nanoparticle
systems, as well as liposomal and emulsion systems, that are now
advancing in nanomedicines development.

The TheraCour polymers result in polymeric micelles that can be used to
encapsulate active pharmaceutical ingredients (APIs) to develop superior
drugs where needed. Of greater importance to NanoViricides, they are
capable of direct targeting to any desired surface with defined
specificity, such as a virus particle.

The current first generation nanoviricides® drug candidates have
achieved very high levels of effectiveness only by employing the
specific targeting ability of the TheraCour polymer systems. These first
generation drugs did not require encapsulation of any additional APIs to
achieve their high levels of effectiveness. The Company believes this
has simplified the drug approval process for us, because the
specifically targeted nanoviricide polymer we make is itself the drug in
these cases.

In addition, with this technology, the Company has the ability to
develop drugs against intractable viral diseases wherein very little
virus may be present in circulation. In such cases, the Company can
employ the approach of encapsulating multiple antiviral APIs that act by
orthogonal mechanisms, and deliver the payload specifically to infected
cells by using ligands that bind preferentially to infected cells. Drug
combinations are known to often provide enhanced synergistic
effectiveness, and have been approved in viral diseases such as HIV/AIDS
and Hepatitis C. The encapsulation approach is known to be superior to
the simple formulated “fixed drug” combinations approach that is being
employed at present. Nevertheless, fixed drug combinations result in the
conventional approach of attacking all cells, and are not restricted to
attacking infected cells preferentially, and thus are expected to be
relatively toxic. Our next generation nanoviricides approach is
anticipated to require significant further development and resources.
The Company is therefore focusing at present on its wide drug pipeline
of six antiviral projects, namely injectable FluCide™, oral FluCide™,
DengueCide™, HerpeCide™, HIVCide™, and the broad-spectrum drug for viral
diseases of the external eye.

In addition to this basic PCT application that covers the “pi-polymer”
structure itself, another PCT application that discloses making
antiviral agents from the TheraCour family of polymers and such
structures is in various stages of prosecution in several countries, and
has already issued in at least seven countries and regions.

The original “pi-polymer” international application was filed under the
Patent Cooperation Treaty (PCT) system in 2006. Several other patents
have already been granted previously in this patent family in various
countries and regions, including Canada, Europe, Israel, ARIPO, China,
HongKong, Japan, Mexico, New Zealand, OAPI, Vietnam and South Africa,
and the USA. Prosecution in several other countries continues.

The patents are being issued to the inventors Anil R. Diwan, PhD, Jayant
G. Tatake, PhD, and Ann L. Onton, all of who are among the founders of
NanoViricides, Inc. The patents have been assigned to AllExcel, Inc.,
the Company at which the ground-breaking work was performed. AllExcel,
Inc. has contractually transferred this intellectual property to
TheraCour Pharma, Inc.

NanoViricides,
Inc. (www.nanoviricides.com)
is a development stage company that is creating special purpose
nanomaterials for antiviral therapy. The Company's novel nanoviricide®
class of drug candidates are designed to specifically attack enveloped
virus particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1 bird
flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of
the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events
could differ materially and substantially from those projected herein
and depend on a number of factors. Certain statements in this release,
and other written or oral statements made by NanoViricides, Inc. are
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. You should not place undue reliance on forward-looking statements
since they involve known and unknown risks, uncertainties and other
factors that are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no obligation
to publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if new
information becomes available in the future. Important factors that
could cause actual results to differ materially from the company's
expectations include, but are not limited to, those factors that are
disclosed under the heading "Risk Factors" and elsewhere in documents
filed by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although it is
not possible to predict or identify all such factors, they may include
the following: demonstration and proof of principle in pre-clinical
trials that a nanoviricide is safe and effective; successful development
of our product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are seeking; the
successful commercialization of our product candidates; and market
acceptance of our products.